Viewing Study NCT05422794


Ignite Creation Date: 2025-12-25 @ 1:44 AM
Ignite Modification Date: 2026-02-26 @ 4:18 PM
Study NCT ID: NCT05422794
Status: RECRUITING
Last Update Posted: 2025-10-27
First Post: 2022-06-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Sponsor: National Cancer Institute (NCI)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module